Andreas Schrödter

Investigations on the pharmacokinetic properties of <i>Harpagophytum</i> extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo

D. Loew, Jörg Möllerfeld, Andreas Schrödter et al. · Clinical Pharmacology & Therapeutics · 2001 · 82 citations

Inhibition of Noxious Stimulus‐Induced Spinal Prostaglandin E₂ Release by Flurbiprofen Enantiomers

Gerd Geißlinger, Uta Muth‐Selbach, Ovidiu Coste et al. · Journal of Neurochemistry · 2000 · 46 citations

Pain Medicine, Anesthetic Mechanism, Neuropathic Pain +19

Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long‐Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants

Josep M. Jansat, Rosa Lamarca, Gonzalo de Miquel et al. · The Journal of Clinical Pharmacology · 2009 · 43 citations

Asthma, Pharmacological Study, Multiple Doses +14

Promoter Polymorphisms of UCP1, UCP2, and UCP3 are not Associated with Diabetic Microvascular Complications in Type 2 Diabetes

Gottfried Rudofsky, Andreas Schrödter, Andrea Schlotterer et al. · Hormone and Metabolic Research · 2007 · 20 citations

Metabolic Syndrome, Genetic Determinant, Cardiovascular Disease +15

Bioavailability of β-aescin from horse chestnut seed extract: Comparative clinical studies of two galenic formulations

Dagmar Bässler, S Okpanyi, Andreas Schrödter et al. · Advances in Therapy · 2003 · 14 citations

Pharmacology, Nutraceutical Ingredient, Galenic Formulations +1